By Robert M. DiSogra This article is a part of the May/June 2020, Volume 32, Volume 3, Audiology Today issue. In an effort to combat the coronavirus (COVID-19), front-line physicians are re-purposing two drugs: hydroxychloroquine (commonly used for malaria and rheumatoid arthritis) and azithromycin (a macrolide antibiotic used to treat common infections of the respiratory system, the ear and the eye). Both drugs are known ototoxic agents; however, there is no published research about the synergistic ototoxic effects of these drugs in treating COVID-19. At the present time, it is not known if hearing loss and/or tinnitus will be a late onset side effect of this COVID-19 drug intervention. Therefore, case history questions will need to be added to accommodate this new population of patients. COVID-19 Infection The coronavirus disease was identified in 2019 and named/identified as “COVID-19.” The virus is a microscopic parasitic microbe. Once inhaled, the virus will attach itself to the cell’s membrane then duplicate itself destroying more cells in the process. The associated respiratory distress can lead to death. This content is an exclusive benefit for American Academy of Audiology members. If you're a member, log in and you'll get immediate access. Member Login If you're not yet a member, you'll be interested to know that joining not only gives you access to top-notch resources like this one, but also invitations to member-only events, inclusion in the member directory, participation in professional forums, and access to patient resources, tools, and continuing education. Join today!